AstraZeneca Crestor Should Be Withdrawn For Safety Reasons, Public Citizen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Petition cites 22 cases of "serious" post-marketing events, including rhabdomyolysis, kidney problems and bleeding, in the U.S., U.K. and Canada.
You may also be interested in...
Crestor May Be Safer Than Other Statins, FDA Tells Public Citizen
There is no evidence to suggest Crestor (rosuvastatin) should be withdrawn because of its renal or muscle toxicity profiles, FDA says in its rejection of Public Citizen's petition. "For any degree of LDL-lowering, rosuvastatin is as safe, and may well be safer than, any other marketed statin with regard to muscle toxicity," FDA says.
Crestor May Be Safer Than Other Statins, FDA Tells Public Citizen
There is no evidence to suggest Crestor (rosuvastatin) should be withdrawn because of its renal or muscle toxicity profiles, FDA says in its rejection of Public Citizen's petition. "For any degree of LDL-lowering, rosuvastatin is as safe, and may well be safer than, any other marketed statin with regard to muscle toxicity," FDA says.
Celebrex, Bextra To Be Targets Of Public Citizen Withdrawal Petition
The watchdog group plans to file a petition in the next week calling for the withdrawal of Pfizer's COX-2 inhibitors. Celebrex and Bextra are among 180 currently marketed drugs Public Citizen advises consumers "do not use" on its expanded worstpills.org website.